You will move to an external webpage. Are you sure?

Nobelpharma

News & Press Release

  • 2018-06-06 Product Information

Launch of RAPALIMUS® GEL 0.2% SAKIGAKE Designation & Orphan Drug Designation Treatment for Angiofibroma in Tuberous Sclerosis Complex

  1. 前の記事へ
  2. 一覧へ戻る（英語）
  3. 次の記事へ
PAGE TOP
  1. HOME
  2. News & Press Release
  3. Launch of RAPALIMUS® GEL 0.2% SAKIGAKE Designation & Orphan Drug Designation Treatment for Angiofibroma in Tuberous Sclerosis Complex